Literature DB >> 10836275

Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.

S K Moshkani1, A Dalimi.   

Abstract

Mice were infected intraperitoneally with 10,000 tachyzoites of Toxoplasma gondii (RH) strain and, 24 h later, were treated orally for 10 days with atovaquone and azithromycin, either alone or in combination. Evaluation of the efficacy of the drugs was performed by microscopic examination of smears prepared from the organs of the mice, and by subinoculation of visceral and brain suspensions from surviving mice into healthy mice at the end of the experiments. It was found that 58%, 83% and 100% of the mice survived after administration of 75, 150 or 200 mg/kg per day of azithromycin, respectively. Moreover, 8%, 17% and 25% of the mice survived after treatment with atovaquone at 20, 50 or 100 mg/kg per day, respectively. No synergistic or additive effects of combinations of atovaquone and azithromycin were observed. However, azithromycin did not eradicate the parasite from the brain and viscera of the infected mice, whereas atovaquone at 20, 50 and 100 mg/kg per day removed the parasite from viscera and at 100 mg/kg per day eradicated the parasite from the brain of infected mice. The combinations of atovaquone and azithromycin failed to completely eradicate the parasite from the brain and viscera of infected mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836275     DOI: 10.1023/a:1006404314523

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  17 in total

1.  Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.

Authors:  J Huskinson-Mark; F G Araujo; J S Remington
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

2.  In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.

Authors:  S Romand; C Della Bruna; R Farinotti; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.

Authors:  F G Araujo; J Huskinson; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

4.  Rifabutin is active in murine models of toxoplasmosis.

Authors:  F G Araujo; T Slifer; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

5.  Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program.

Authors:  J A Kovacs
Journal:  Lancet       Date:  1992-09-12       Impact factor: 79.321

6.  Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.

Authors:  F Derouin; R Almadany; F Chau; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

7.  Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.

Authors:  S Chamberland; H A Kirst; W L Current
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

8.  In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.

Authors:  S Romand; M Pudney; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

9.  The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.

Authors:  F G Araujo; T Lin; J S Remington
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

10.  Activity of A-56268 (TE-031), a new macrolide, against Toxoplasma gondii in mice.

Authors:  H R Chang; F C Rudareanu; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

View more
  1 in total

Review 1.  Pyrimidine metabolism in schistosomes: A comparison with other parasites and the search for potential chemotherapeutic targets.

Authors:  Mahmoud H El Kouni
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2017-07-21       Impact factor: 2.231

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.